

THE PATH TO < 500 IN SEVERE HYPERTRIGLYCERIDEMIA

Authors: Christie M. Ballantyne, MD; Pradeep Natarajan, MD, MMSC

Supported by an independent educational grant from Arrowhead Pharmaceuticals, Inc.

Target Audience and Goal Statement

This educational activity is intended for endocrinologists/diabetologists, primary care physicians, cardiologists, physician assistants, nurse practitioners, and nurses in the United States.

The goal of this activity is for learners to be better able to identify guideline recommendations for triglyceride levels and evaluate the latest evidence for apolipoprotein C-III (APOC3) inhibition for the treatment of severe hypertriglyceridemia (sHTG).

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
 - Management of patients with sHTG, including the importance of achieving TG levels below 500 mg/dL
 - Emerging data on APOC3 inhibition as a treatment strategy for sHTG

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Christie M. Ballantyne, MD

Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, Texas

Christie M. Ballantyne, MD, has the following relevant financial relationships:

Consultant or advisor for: Abbott Diagnostics; Amgen; Arrowhead Pharmaceuticals, Inc; AstraZeneca; Denka Seiken; Esperion; Illumina; Ionis; Lilly; Merck; New Amsterdam; Novartis; Novo Nordisk; Roche Diagnostic
Research funding from: Abbott Diagnostic; Akcea; Amgen; Arrowhead; Esperion; Ionis; Merck; New Amsterdam; Novartis; Novo Nordisk; Regeneron; Roche Diagnostic

Pradeep Natarajan, MD, MMSC

Director of Preventive Cardiology
Massachusetts General Hospital
Paul & Phyllis Fireman Endowed Chair in Vascular Medicine
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Pradeep Natarajan, MD, MMSC, has the following relevant financial relationships:

Consultant or advisor for: Allelica; Apple; AstraZeneca; Bain Capital; Blackstone Life Sciences; Bristol Myers Squibb; Creative Education Concepts; CRISPR Therapeutics; Eli Lilly & Co; Esperion Therapeutics; Foresite Capital; Foresite Labs; Genentech/Roche; GV; HeartFlow; Magnet Biomedicine; Merck; Novartis; Novo Nordisk; TenSixteen Bio; Tourmaline Bio
Research funding from: Allelica; Amgen; Apple; Boston Scientific; Genentech/Roche; Novartis
Stock options from: Bolt; Candela; Mercury; MyOme; Parameter Health; Preciseli; TenSixteen Bio

Editor

Anne Sendaydiego, PharmD

Medical Education Director, Medscape Education

Anne Sendaydiego, PharmD, has no relevant financial relationships.

Disclaimer

- The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
 - The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
 - Medscape Education © 2024 Medscape, LLC
-